{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/686d1f30bf84bb51483a2e48/686d1f388d2a216e127c3280?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The role of selinexor in early rrMM and sequencing in 2024.","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/686d1f30bf84bb51483a2e48/62740c216f40c7e063f3ef358171471e.jpg?height=200","description":"<p>In this episode of &quot;Science for the Real World: Canadian Hematology Today,&quot; Dr. Peter Anglin hosts a discussion with Dr. Joshua Richter and Dr. Darrell White on the management of early rrMM in 2024, focusing on the role of selinexor and treatment sequencing.</p>\n<p><br></p>","author_name":"Catalytic Health"}